Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Sasine on Determining Outlook With CAR T-Cell Therapy in Hematologic Cancers

Joshua P. Sasine, MD, PhD
Published: Monday, Aug 26, 2019



Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Currently, it is difficult to determine who is going to benefit the most from CAR T-cell therapy, according to Sasine. However, researchers are getting closer to that because there are certain cytokine profiles now known, both before and after CAR T cells are given, that are associated with long-term, durable remissions, explains Sasine.

Lymphodepletion can also be a signal to determine response to CAR T cell therapy. This is something that can be modified within a physician's control, whereas other aspects are unmodifiable but can be helpful for predicting response.
SELECTED
LANGUAGE


Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Currently, it is difficult to determine who is going to benefit the most from CAR T-cell therapy, according to Sasine. However, researchers are getting closer to that because there are certain cytokine profiles now known, both before and after CAR T cells are given, that are associated with long-term, durable remissions, explains Sasine.

Lymphodepletion can also be a signal to determine response to CAR T cell therapy. This is something that can be modified within a physician's control, whereas other aspects are unmodifiable but can be helpful for predicting response.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x